Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

DNA Virus Infections

ClinicalTrials.gov lists 5,338 trials for DNA Virus Infections or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 327.

MeSH D004266 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 889 Phase 1/2 Phase 1/2 314 Phase 2 Phase 2 991 Phase 2/3 Phase 2/3 68 Phase 3 Phase 3 711 Phase 4 Phase 4 520 Not applicable Not applicable 761 Observational Observational 1,068 Phase 1 Phase 1 889 Phase 1/2 Phase 1/2 314 Phase 2 Phase 2 991 Phase 2/3 Phase 2/3 68 Phase 3 Phase 3 711 Phase 4 Phase 4 520 Not applicable Not applicable 761 Observational Observational 1,068

Trials per phase

2 more sections with rows

27 of the 5,338 trials are tagged with DNA Virus Infections itself; the rest are tagged with a narrower condition beneath it.

Get the DNA Virus Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did DNA Virus Infections trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 8 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 266

1990: 6 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 3) 1991: 4 trials (Observational 1, Phase 3 1, Phase 2 2) 1992: 19 trials (Observational 4, Phase 3 5, Phase 2 7, Phase 1 3) 1993: 8 trials (Observational 1, Phase 3 1, Phase 2 5, Phase 1 1) 1994: 9 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1 2) 1995: 22 trials (Observational 2, Phase 4 1, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 4, Phase 1 3) 1996: 24 trials (Observational 6, Phase 3 3, Phase 2 7, Phase 1 8) 1997: 50 trials (Observational 4, Not applicable 3, Phase 3 15, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 12) 1998: 53 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 4, Phase 2/3 2, Phase 2 21, Phase 1/2 3, Phase 1 16) 1999: 69 trials (Observational 5, Not applicable 4, Phase 3 16, Phase 2 15, Phase 1/2 6, Phase 1 23) 2000: 73 trials (Observational 8, Not applicable 5, Phase 4 2, Phase 3 15, Phase 2 22, Phase 1/2 3, Phase 1 18) 2001: 56 trials (Observational 9, Not applicable 4, Phase 4 2, Phase 3 10, Phase 2 17, Phase 1/2 2, Phase 1 12) 2002: 82 trials (Observational 9, Not applicable 7, Phase 4 5, Phase 3 14, Phase 2/3 1, Phase 2 22, Phase 1/2 5, Phase 1 19) 2003: 106 trials (Other 1, Observational 9, Not applicable 9, Phase 4 12, Phase 3 24, Phase 2 29, Phase 1/2 9, Phase 1 13) 2004: 143 trials (Observational 15, Not applicable 13, Phase 4 16, Phase 3 34, Phase 2/3 2, Phase 2 33, Phase 1/2 6, Phase 1 24) 2005: 147 trials (Observational 22, Not applicable 14, Phase 4 16, Phase 3 35, Phase 2/3 2, Phase 2 34, Phase 1/2 8, Phase 1 16) 2006: 179 trials (Other 1, Observational 22, Not applicable 12, Phase 4 15, Phase 3 56, Phase 2/3 2, Phase 2 35, Phase 1/2 6, Phase 1 30) 2007: 191 trials (Other 1, Observational 31, Not applicable 15, Phase 4 27, Phase 3 39, Phase 2/3 3, Phase 2 39, Phase 1/2 7, Phase 1 29) 2008: 171 trials (Observational 36, Not applicable 16, Phase 4 31, Phase 3 38, Phase 2/3 2, Phase 2 21, Phase 1/2 6, Phase 1 21) 2009: 171 trials (Other 1, Observational 39, Not applicable 22, Phase 4 28, Phase 3 18, Phase 2/3 3, Phase 2 31, Phase 1/2 6, Phase 1 23) 2010: 184 trials (Observational 53, Not applicable 19, Phase 4 23, Phase 3 27, Phase 2/3 3, Phase 2 31, Phase 1/2 9, Phase 1 19) 2011: 171 trials (Observational 44, Not applicable 19, Phase 4 25, Phase 3 36, Phase 2/3 1, Phase 2 20, Phase 1/2 9, Phase 1 17) 2012: 168 trials (Observational 43, Not applicable 17, Phase 4 22, Phase 3 33, Phase 2 20, Phase 1/2 15, Phase 1 18) 2013: 165 trials (Observational 37, Not applicable 17, Phase 4 32, Phase 3 22, Phase 2/3 1, Phase 2 21, Phase 1/2 8, Phase 1 27) 2014: 171 trials (Observational 34, Not applicable 23, Phase 4 20, Phase 3 24, Phase 2/3 7, Phase 2 30, Phase 1/2 9, Phase 1 24) 2015: 192 trials (Observational 34, Not applicable 20, Phase 4 37, Phase 3 18, Phase 2/3 3, Phase 2 43, Phase 1/2 9, Phase 1 28) 2016: 187 trials (Observational 42, Not applicable 31, Phase 4 23, Phase 3 14, Phase 2/3 4, Phase 2 30, Phase 1/2 13, Phase 1 30) 2017: 194 trials (Observational 42, Not applicable 29, Phase 4 20, Phase 3 18, Phase 2/3 1, Phase 2 35, Phase 1/2 14, Phase 1 35) 2018: 189 trials (Observational 38, Not applicable 31, Phase 4 19, Phase 3 12, Phase 2/3 4, Phase 2 39, Phase 1/2 16, Phase 1 30) 2019: 220 trials (Observational 37, Not applicable 42, Phase 4 17, Phase 3 22, Phase 2/3 2, Phase 2 41, Phase 1/2 14, Phase 1 45) 2020: 219 trials (Observational 46, Not applicable 41, Phase 4 18, Phase 3 15, Phase 2/3 3, Phase 2 40, Phase 1/2 11, Phase 1 45) 2021: 228 trials (Observational 59, Not applicable 31, Phase 4 23, Phase 3 18, Phase 2/3 3, Phase 2 39, Phase 1/2 15, Phase 1 40) 2022: 264 trials (Observational 66, Not applicable 46, Phase 4 21, Phase 3 22, Phase 2/3 2, Phase 2 44, Phase 1/2 20, Phase 1 43) 2023: 254 trials (Observational 70, Not applicable 40, Phase 4 13, Phase 3 15, Phase 2 41, Phase 1/2 20, Phase 1 55) 2024: 245 trials (Observational 76, Not applicable 59, Phase 4 12, Phase 3 11, Phase 2/3 4, Phase 2 31, Phase 1/2 15, Phase 1 37) 2025: 266 trials (Observational 61, Not applicable 67, Phase 4 13, Phase 3 21, Phase 2/3 6, Phase 2 36, Phase 1/2 21, Phase 1 41)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 212
2025 266
2024 245
2023 254
2022 264
2021 228
2020 219
2019 220
2018 189
2017 194

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 250 trials starting in 2026 and about 260 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 459 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 3,136 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are DNA Virus Infections trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 889
Phase 1/2 314
Phase 2 991
Phase 2/3 68
Phase 3 711
Phase 4 520
Not applicable 761
Observational 1,068
Expanded access 15
Unknown 1

How many DNA Virus Infections trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 211
Recruiting 521
Enrolling by invitation 37
Active, not recruiting 246
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most DNA Virus Infections trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
GlaxoSmithKline 327
National Cancer Institute (NCI) 186
National Institute of Allergy and Infectious Diseases (NIAID) 182
Merck Sharp & Dohme LLC 129
Hoffmann-La Roche 71

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for DNA Virus Infections? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 227
Entecavir 152
RITUXIMAB 115
GS-7340 73

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 125
tenofovir disproxil fumarate 113
Etoposid 104
Peripheral blood stem cell transplantation 95
Filgrastime (G-CSF) 94

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do DNA Virus Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,859 201
Febrile neutropenia 1,184 88
Neutrophil count decreased 1,108 41
Platelet count decreased 891 39
Sepsis 887 146

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover DNA Virus Infections? (16)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Immune Monitoring Goes Viral - Torque Teno Virus for Immunologic Risk Stratification After Kidney Transplantation. Transplant international : official journal of the European Society for Organ Transplantation 2025 Yes
Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy. Bone marrow transplantation 2024 Yes
Genomic Diversity of Torque Teno Virus in Blood Samples from Febrile Paediatric Outpatients in Tanzania: A Descriptive Cohort Study. Viruses 2022 Yes
Torque Teno Virus Load Is Associated With Subclinical Alloreactivity in Kidney Transplant Recipients: A Prospective Observational Trial. Transplantation 2021 Yes
Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically Ill Patients: A Single-Centre Prospective Longitudinal Study. Frontiers in immunology 2021 Yes

Showing 5 of 16 publications.

Start your 14-day trial Email me all 16 publications as a PDF

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages